Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving Topical Corticosteroids (TCS)
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Nemolizumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Galderma
- 29 Sep 2021 According to a Galderma media release, results were presented at the virtual 30th EADV congress.
- 29 Sep 2021 Results published in Galderma Media Release
- 01 Jul 2021 Results (n=94) of post analysis hoc analysis evaluating efficacy in patients with baseline EASI scores> 16 at week 16 and secondary endpoint, published in the Journal of the European Academy of Dermatology and Venereology